Ligand Participates in the Initiation of Th 2 Responses during Airway Inflammation *
Caixia Di,Xiaoliang Lin,Yanjie Zhang,Wenwei Zhong,Yufan Yuan,Tong Zhou,Junling Liu,Zhenwei Xia
2015-01-01
Abstract:Asthma is characterized by increased airway submucosal infiltration of T helper (Th) cells and myeloid cells that co-conspire to sustain a chronic inflammation. While recent studies have demonstrated that the myeloid basophils promote Th2 cells in response to various types of allergens, the underlying mechanisms are poorly understood. Here, we found for the first time that in a mouse model of allergic asthma basophils highly expressed OX40 ligand (OX40L) after activation. Interestingly, blockade of OX40-OX40L interaction suppressed basophils-primed Th2 cell differentiation in vitro and ameliorated ovalbumin (OVA)-induced allergic eosinophilic inflammation mediated by Th2 activation. In accordance, the adoptive transfer of basophils derived from mediastinal lymph nodes (MLN) of OVA-immunized mice triggered a robust Th2 response and eosinophilic inflammation in wild-type mice but largely muted in OX40 mice and mice receiving OX40L-blocked basophils. Taken together, our results reveal a critical role of OX40L presented by the activated basophils to initiate Th2 responses in an allergic asthma model, implicating OX40-OX40L signaling as a potential therapeutic target in the treatment of allergic airway inflammation. ______________________________________ Asthma is a chronic disease that has seen its prevalence rise worldwide due to deteriorating environmental conditions. This has cost a heavy burden on patients and societies alike. Despite the uses of inhaled corticosteroids and long-acting http://www.jbc.org/cgi/doi/10.1074/jbc.M115.642637 The latest version is at JBC Papers in Press. Published on April 3, 2015 as Manuscript M115.642637 Copyright 2015 by The American Society for Biochemistry and Molecular Biology, Inc. by gest on A ril 1, 2015 hp://w w w .jb.org/ D ow nladed from Basophils potentiate Th2 responses in asthma 2 beta agonists that focus on effective symptomatic relief, there is little advancement in disease modifying therapies that target the underlying immune mechanisms. Pathophysiologically, it is increasingly recognized that asthma is characterized by the increased airway submucosal infiltration of not only the previously identified culprits⎯CD4 T helper (Th) cells and eosinophils but also the mast cells and basophils, which together causes mucus hypersecretion, intermittent airway hyperresponsiveness and airway remodeling (1,2). Accumulative studies suggest that an aberrant Th2 immune response, traditionally defined by the over-production of IL-4, IL-5 and IL-13, plays a central role in the pathogenesis of asthma (3,4). Therefore, clarification of the mechanism underlying the initiation of Th2 responses is crucial to anti-asthmatic therapies based on key moleculestargeting. Basophils, which are cells derived from basophil/mast cell precursor cells in the bone marrow, comprise less than 1% of the blood leukocytes and share some characteristics with mast cells phenotypically and functionally, such that they both can act as important effector cells in allergic airway inflammation (5,6). Numerous studies have demonstrated that basophils not only play crucial roles in the effector phase, but also critically participate in the initiation of Th2-centered immune responses (7-11). Using an ovalbumin (OVA)-induced allergic airway inflammation mouse model, we previously showed that basophils acted as a primary inducer of the Th2 immunity, evident by increased OVA-specific immunoglobulin E (OVA-sIgE) and IL-4 levels both in serum and bronchial alveolar lavage fluid (BALF), and increased proportion of Th2 cells in the spleen after transfusion of lung basophils derived from OVA-challenged mice into wild-type (WT) mice (12). We also found that pulmonary basophils were capable of antigen uptake, expressed an array of molecular markers such as CD40, CD80/86 and MHC II and released high levels of IL-4 following OVA sensitization and challenge. Taken together, these observations support the notion that basophils possess the activity to initiate Th2 cell responses (7-9). However, the underlying mechanisms entitling basophils as the key initiator in the Th2 immune responses remain to be elucidated. The antigen recognition by TCR, ligation of co-stimulatory molecules and corresponding cytokines such as IL-4 for Th2 cells are crucial for the induction of naïve T cells to effector Th2 cells. Recent studies suggest that OX40 (CD134)-OX40 ligand (OX40L, CD252) interaction contributes greatly to the differentiation of some Th subsets,such as Th9 cells, Th2 cells and Tregs (13-15). OX40, a member of tumor necrosis factor receptor (TNFR) superfamily, is mainly expressed on activated T cells, including CD4 T cells and CD8 T cells (16,17). OX40L, which belongs to the TNF superfamily, is likely to be induced on activated professional antigen presenting cells (APCs), such as B cells, macrophages and mature conventional dendritic cells (DCs) (18-20). In addition, non-APCs such as NK cells, smooth muscle cells and monocytes can also express OX40L in inflammatory diseases (21-23). Notably, OX40-OX40L interaction is bi-directional and thus plays a potential role in regulation of not only T cell function but also APC activation and maturation. OX40 signaling promotes T cell proliferation and survival, while OX40L signaling favors maturation and cytokine production of APCs (16,24). Furthermore, OX40-OX40L interaction is crucial for optimal T cell activation through the NF-κB pathway, especially in CD4 T cells (25). Interestingly, in the context of atopic dermatitis in mice, OX40-OX40L signaling pathway has a critical role in Th2 priming (14). Nevertheless, a key issue remains unaddressed regarding whether OX40-OX40L interaction is also involved in the Th2 initiation when being primed by basophils in asthma. Data from animal and human studies have confirmed a critical role of OX40-OX40L interaction in allergic airway inflammation. Studies have showed an increased expression of OX40 and OX40L on the immune cells in the airway submucosa of patients with mild asthma, and their expression was related to the level of IL-4 and the number of eosinophils in the lung (26). In a murine model, OX40 mice sensitized and challenged with OVA showed significant alleviation of inflammation, characterized by reduced levels of serum IgE and inflammatory cytokines, as well as a decreased number of eosinophils in lungs compared with that in WT mice (27,28). In this study, we aim to further determine if basophils play a primary role in by gest on A ril 1, 2015 hp://w w w .jb.org/ D ow nladed from Basophils potentiate Th2 responses in asthma 3 inducing naïve T cells to differentiate into Th2 cells and promoting Th2 responses and eosinophilia via OX40-OX40L interaction in a murine model of OVA-induced allergic eosinophilic airway inflammation. EXPERIMENTAL PROCEDURES Mice—OX40 mice (C57BL/6 genetic background) and DO11.10 mice (BALB/c genetic background) were purchased from the Jackson Laboratory (Bar Harbor, Maine, USA) and Model Animal Research Center of Nanjing University, respectively. WT C57BL/6 mice and BALB/c mice (Shanghai Laboratory Animal Co., Ltd., China) were used. CD40 mice (BALB/c genetic background) were provided by Professor David Hinrichs at the Portland VA Medical Center. Six-to-eight-week-old mice were used for all experiments and maintained in the specified-pathogen-free (SPF) facilities in the Research Center for Experimental Medicine of Ruijin Hospital affiliated with Shanghai Jiao Tong University School of Medicine. All animal procedures were approved by Ruijin Hospital Animal Ethics Committee. Cell culture, isolation and identification of bone marrow-derived basophils (BM-Bas)—To obtain BM-Bas, bone marrow cells were cultured at a density of 2×10 cells per 1 ml for 10 days in the presence of 15 ng/ml recombinant mouse IL-3 (rIL-3, R&D Systems) in RPMI 1640 medium supplemented with 10% (vol/vol) fetal bovine serum (FBS), 100 U/ml penicillin and streptomycin, 55 μmol/L β-mercaptoethanol (β-ME), 2 mmol/L of L-glutamine and 0.1 mmol/L non-essential amino acids (RPMI 1640 complete medium) (9,29). On days 4 and 7, half of the medium was replaced by fresh medium. On day 10, the cells were collected, washed twice, stained with PE/Cy7-conjugated anti-mouse FcεRIα (clone MAR-1), FITC-conjugated anti-mouse CD49b (pan-NK cells, clone DX5), Alexa Fluor® 700-conjugated anti-mouse CD11c (clone N418) and APC-conjugated anti-mouse CD117 (c-Kit, clone 2B8) (Biolegend) and then sorted by fluorescence-activated cell sorter (FACS) in accordance with negative staining for CD117 and CD11c and positive staining for FcεRIα and CD49b as well as small FSC and SSC within the lymphocyte gate. Sorted FSC SSC low CD117 CD11c CD49b FcεRI BM-Bas cells were stained with propidium iodide (PI) and assessed cell viability by FACS. To characterize the sorted BM-Bas, cytospins were made. A part of them were stained with Wright-Giemsa and the others were fixed with 4% (vol/vol) paraformaldehyde, then permeated with 0.1% (vol/vol) Triton 100 and blocked with 10% (wt/vol) bovine serum albumin, stained with purified anti-mMCP-8 antibody (Ab) (clone TUG8, Biolegend) and FITC-conjugated rabbit polyclonal secondary Ab to rat, and counterstained with DAPI (4,6-diamidino-2-phenylindole) (30,31). Th2 cell differentiation in vitro—Naïve CD4 T cells (CD3 CD4 CD62L CD44) from spleens were isolated via a negative selection principle by MagCellect (R&D Systems) following the manufacturer’s instructions. For the initiation of Th2 cells, BM-Bas (2.5×10 per well) and naïve CD4 T cells (5×10 per well) were seeded in 96-well plates in RPMI 1640 complete medium in the presence of rIL-2 (20 U/ml, R&D Systems), rIL-3 (30 ng/ml), DNP-OVA (100 μg/ml, Biosearch Technologies, Novato) and anti-DNP IgE (10 μg/ml, Sigma-Aldrich) for 5 days (7,12). For some experiments, anti-mouse CD252 (20 μg/ml, OX40L blocking Ab, αOX40L, eBioscience) was added to the cultures. On day 3, fresh RPMI 1640 complete medi